Paolo Perri

Prof. Paolo Perri


Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2012 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
FPFrancesco Parmeggiani
Francesco Parmeggiani
MRMario R. Romano
Mario R. Romano
CCCiro Costagliola
Ciro Costagliola
FSFrancesco Semeraro
Francesco Semeraro
CICarlo Incorvaia
Carlo Incorvaia
ASAdolfo Sebastiani
Adolfo Sebastiani
Age-related macular degeneration (AMD) is a multifactorial disease that represents the most common cause of irreversible visual impairment among people over the age of 50 in Europe, the United States, and Australia, accounting for up to 50% of all cases of central blindness. Risk factors of AMD are heterogeneous, mainly including increasing age and different genetic predispositions, together with several environmental/epigenetic factors, that is, cigarette smoking, dietary habits, and phototoxic exposure. In the aging retina, free radicals and oxidized lipoproteins are considered to be major causes of tissue stress resulting in local triggers for parainflammation, a chronic status which contributes to initiation and/or progression of many human neurodegenerative diseases such as AMD. Experimental and clinical evidences strongly indicate the pathogenetic role of immunologic processes in AMD occurrence, consisting of production of inflammatory related molecules, recruitment of macrophages, complement activation, microglial activation and accumulation within those structures that compose an essential area of the retina known as macula lutea. This paper reviews some attractive aspects of the literature about the mechanisms of inflammation in AMD, especially focusing on those findings or arguments more directly translatable to improve the clinical management of patients with AMD and to prevent the severe vision loss caused by this disease.

26 May 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
CGCarla Enrica Gallenga
Carla Enrica Gallenga
MLMaria Lonardi
Maria Lonardi
SPSofia Pacetti
Sofia Pacetti
SVSara Silvia Violanti
Sara Silvia Violanti
PTPaolo Tassinari
Paolo Tassinari
PPPaolo Perri
Paolo Perri
Retinitis pigmentosa (RP) is an inherited retinopathy. Nevertheless, non-genetic biological factors play a central role in its pathogenesis and progression, including inflammation, autophagy and oxidative stress. The retina is particularly affected by oxidative stress due to its high metabolic rate and oxygen consumption as well as photosensitizer molecules inside the photoreceptors being constantly subjected to light/oxidative stress, which induces accumulation of ROS in RPE, caused by damaged photoreceptor’s daily recycling. Oxidative DNA damage is a key regulator of microglial activation and photoreceptor degeneration in RP, as well as mutations in endogenous antioxidant pathways involved in DNA repair, oxidative stress protection and activation of antioxidant enzymes (MUTYH, CERKL and GLO1 genes, respectively). Moreover, exposure to oxidative stress alters the expression of micro-RNA (miRNAs) and of long non-codingRNA (lncRNAs), which might be implicated in RP etiopathogenesis and progression, modifying gene expression and cellular response to oxidative stress. The upregulation of the P2X7 receptor (P2X7R) also seems to be involved, causing pro-inflammatory cytokines and ROS release by macrophages and microglia, contributing to neuroinflammatory and neurodegenerative progression in RP. The multiple pathways analysed demonstrate that oxidative microglial activation may trigger the vicious cycle of non-resolved neuroinflammation and degeneration, suggesting that microglia may be a key therapy target of oxidative stress in RP.

27 November 2013 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
FPFrancesco Parmeggiani
Francesco Parmeggiani
FSFrancesco S. Sorrentino
Francesco S. Sorrentino
MRMario R. Romano
Mario R. Romano
CCCiro Costagliola
Ciro Costagliola
FSFrancesco Semeraro
Francesco Semeraro
MRMichele Rubini
Michele Rubini
Age-related macular degeneration (AMD) is the most common cause of irreversible visual impairment among people over 50 years of age, accounting for up to 50% of all cases of legal blindness in Western countries. Although the aging represents the main determinant of AMD, it must be considered a multifaceted disease caused by interactions among environmental risk factors and genetic backgrounds. Mounting evidence and/or arguments document the crucial role of inflammation and immune-mediated processes in the pathogenesis of AMD. Proinflammatory effects secondary to chronic inflammation (e.g., alternative complement activation) and heterogeneous types of oxidative stress (e.g., impaired cholesterol homeostasis) can result in degenerative damages at the level of crucial macular structures, that is photoreceptors, retinal pigment epithelium, and Bruch’s membrane. In the most recent years, the association of AMD with genes, directly or indirectly, involved in immunoinflammatory pathways is increasingly becoming an essential core for AMD knowledge. Starting from the key basic-research notions detectable at the root of AMD pathogenesis, the present up-to-date paper reviews the best-known and/or the most attractive genetic findings linked to the mechanisms of inflammation of this complex disease.

12 August 2020 in Microorganisms
Verified
Journal Article
Open access
PDF file
Carlo ContiniCarlo Contini
Carlo Contini
Elisabetta CaselliElisabetta Caselli
Elisabetta Caselli
FMFernanda Martini
Fernanda Martini
MMMartina Maritati
Martina Maritati
ETElena Torreggiani
Elena Torreggiani
Mauro TognonMauro Tognon
Mauro Tognon
Until less than two decades ago, all known human coronaviruses (CoV) caused diseases so mild that they did not stimulate further advanced CoV research. In 2002 and following years, the scenario changed dramatically with the advent of the new more pathogenic CoVs, including Severe Acute Respiratory Syndome (SARS-CoV-1), Middle Eastern respiratory syndrome (MERS)-CoV, and the new zoonotic SARS-CoV-2, likely originated from bat species and responsible for the present coronavirus disease (COVID-19), which to date has caused 15,581,007 confirmed cases and 635,173 deaths in 208 countries, including Italy. SARS-CoV-2 transmission is mainly airborne via droplets generated by symptomatic patients, and possibly asymptomatic individuals during incubation of the disease, although for the latter, there are no certain data yet. However, research on asymptomatic viral infection is currently ongoing worldwide to elucidate the real prevalence and mortality of the disease. From a clinical point of view, COVID-19 would be defined as “COVID Planet “ because it presents as a multifaceted disease, due to the large number of organs and tissues infected by the virus. Overall, based on the available published data, 80.9% of patients infected by SARS-CoV-2 develop a mild disease/infection, 13.8% severe pneumonia, 4.7% respiratory failure, septic shock, or multi-organ failure, and 3% of these cases are fatal, but mortality parameter is highly variable in different countries. Clinically, SARS-CoV-2 causes severe primary interstitial viral pneumonia and a “cytokine storm syndrome”, characterized by a severe and fatal uncontrolled systemic inflammatory response triggered by the activation of interleukin 6 (IL-6) with development of endothelitis and generalized thrombosis that can lead to organ failure and death. Risk factors include advanced age and comorbidities including hypertension, diabetes, and cardiovascular disease. Virus entry occurs via binding the angiotensin-converting enzyme 2 (ACE2) receptor present in almost all tissues and organs through the Spike (S) protein. Currently, SARS-CoV-2 infection is prevented by the use of masks, social distancing, and improved hand hygiene measures. This review summarizes the current knowledge on the main biological and clinical features of the SARS-CoV-2 pandemic, also focusing on the principal measures taken in some Italian regions to face the emergency and on the most important treatments used to manage the COVID-19 pandemic.

15 November 2007 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
CCCiro Costagliola
Ciro Costagliola
FPFrancesco Parmeggiani
Francesco Parmeggiani
GVGianni Virgili
Gianni Virgili
GLGiuseppe Lamberti
Giuseppe Lamberti
CICarlo Incorvaia
Carlo Incorvaia
ASAdolfo Sebastiani
Adolfo Sebastiani

1 January 2007 in Current Eye Research
Verified
Journal Article
Closed access
PPPaolo Perri
Paolo Perri
CCClaudio Campa
Claudio Campa
CCCiro Costagliola
Ciro Costagliola
CICarlo Incorvaia
Carlo Incorvaia
SDSergio D'ANgelo
Sergio D'ANgelo
ASAdolfo Sebastiani
Adolfo Sebastiani
Purpose: To investigate retinal blood flow by Heidelberg retina flowmeter in patients with active Graves' ophthalmopathy. Materials and Methods: Thirty patients with active Graves' ophthalmopathy in euthyroid state and thirty normal controls were enrolled in this study. All subjects underwent heart rate, systolic and diastolic blood pressure detection, complete ophthalmological examination, Hertel's exophthalmometry, and retinal blood flow analysis by Heidelberg retina flowmeter. Patients additionally underwent automated threshold perimetry and extraocular muscle thickness measurement by A-scan ecography. Results: A significant statistical difference was found in exophthalmometry (P < 0.001), intraocular pressure (P < 0.001) and retinal blood flow (P < 0.05) between patients and controls. In patients, muscle enlargement was significantly correlated with retinal blood flow (r = 0.49, P = 0.005) and proptosis (r = 0.37, P = 0.04). A significant positive correlation (r = 0.52, P = 0.002) was also found between intraocular pressure and proptosis. Conclusions: Active Graves' ophthalmopathy patients present an increased retinal blood flow.